Inmune Bio, Inc. current report, 14 September 2020

Business Context and Reporting Period

Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2020
Reporting Period: Single event date (September 14, 2020)

The filing serves as a notification of an upcoming corporate event rather than a periodic financial report. The Company is an emerging growth company with common stock trading on The NASDAQ Stock Market LLC under the symbol "INMB."

Key Financial Metrics

This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow information, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.

Material Changes

No material changes to financial condition or operations are reported in this document. The filing solely discloses a scheduled management participation in an investor summit.

Guidance, Outlook, and Events

  • Upcoming Event: Management will participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit on September 23, 2020.
  • Management Commentary: No specific commentary on business outlook, risks, or contingencies is included in this filing.
  • Unusual Items: None reported.

Investor Verification Checklist

  • Verify the date and agenda of the Oppenheimer Fall Healthcare Life Science & Med Tech Virtual Investor Summit (September 23, 2020).
  • Review the attached press release (Exhibit 99.1) for any additional details regarding the summit participation.
  • Consult the Company's most recent 10-Q or 10-K filings for current financial metrics, as this 8-K contains no financial data.